Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion

Transfusion

Volumn 52, Issue 8, 2012, Pages 1696-1702

  Ho, Kwok M ^a,b   Litton, Edward ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; RECOMBINANT ACTIVATED FACTOR VII; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BURN; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRITICAL BLEEDING; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THORAX SURGERY; THROMBOCYTE TRANSFUSION;

ADULT; AGED; BLOOD BANKS; COHORT STUDIES; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; OFF-LABEL USE; RECOMBINANT PROTEINS; REGISTRIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84864974678     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03505.x     Document Type: Article

References (30)

1. Alexander GC, Werner RM, Ubel PA,. The costs of denying scarcity. Arch Intern Med 2004; 164: 593-6.
2. Bochner F, Martin ED, Burgess NG, Somogyi AA, Misan GM,. How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital. BMJ 1994; 308: 901-5.
3. Cookson R, Dolan P,. Principles of justice in health care rationing. J Med Ethics 2000; 26: 323-9.
4. Daniels N, Saloner B, Gelpi AH,. Access, cost, and financing: achieving an ethical health reform. Health Aff (Millwood) 2009; 28: w909-16.
5. Fuchs VR,. New priorities for future biomedical innovations. N Engl J Med 2010; 363: 704-6.
6. Relman AS,. Is rationing inevitable? N Engl J Med 1990; 322: 1809-10.
7. Owens DK, Qaseem A, Chou R, Shekelle P,; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 2011; 154: 174-80.
8. Goodnough LT, Shander AS,. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol 2007; 14: 504-9.
9. Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B,; CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69: 489-500.
10. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS,. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-40.
11. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR,. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleedingâ€"a European perspective. Crit Care 2006; 10: R120.
12. National Health and Medical Research. Council patient blood management guidelines: module 1. Critical bleeding massive transfusion. 2011. [cited 2011 Aug 31]. Available from: http://www.nhmrc.gov.au/-files-nhmrc/publications/ attachments/patient-blood-guidelines-module-1.pdf
13. Ho KM, Leonard AD,. Lack of effect of unrefrigerated young whole blood transfusion on patient outcomes after massive transfusion in a civilian setting. Transfusion 2011; 51: 1669-75.
14. Ho KM, Leonard AD,. Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study. Anaesth Intensive Care 2011; 39: 46-54.
15. Ho KM, Leonard A,. Risk factors and outcome associated with hypomagnesemia in massive transfusion. Transfusion 2011; 51: 270-6.
16. Rechner IJ, Lipman J,. The costs of caring for patients in a tertiary referral Australian intensive care unit. Anaesth Intensive Care 2005; 33: 477-82.
17. Australian Institute of Health and Welfare (AIHW). Australian hospital statistics 2004-2005. AIHW cat. no. HSE 41. Canberra: AIHW Health Services Series no. 26. 2006. [cited 2011 Mar 18]. Available from: http://www.aihw.gov. au/publication-detail/?id=6442468093
18. Pantanowitz L, Kruskall MS, Uhl L,. Cryoprecipitate. Patterns of use. Am J Clin Pathol 2003; 119: 874-81.
19. Waters JR, Meier HH, Waters JH,. An economic analysis of costs associated with development of a cell salvage program. Anesth Analg 2007; 104: 869-75.
20. Toner RW, Pizzi L, Leas B, Ballas SK, Quigley A, Goldfarb NI,. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy 2011; 9: 29-37.
21. Ho KM, Tan JA,. Use of L'Abbé and pooled calibration plots to assess the relationship between severity of illness and effectiveness in studies of corticosteroids for severe sepsis. Br J Anaesth 2011; 106: 528-36.
22. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS,. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-56.
23. Hoffman M, Monroe DM, Roberts HR,. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 Suppl 1: S61-5.
24. Rizoli SB, Boffard KD, Riou B, Warren B, Iau P, Kluger Y, Rossaint R, Tillinger M,; NovoSeven Trauma Study Group. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 2006; 10: R178.
25. Ho KM, Knuiman M, Finn J, Webb SA,. Estimating long-term survival of critically ill patients: the PREDICT model. PLoS ONE 2008; 3: e3226.
26. Ho KM, Burrell M, Rao S,. Extracranial injuries are important in determining mortality of neurotrauma. Crit Care Med 2010; 38: 1562-8.
27. Ho KM, Honeybul S, Litton E,. Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury. Crit Care Med 2011; 39: 2495-500.
28. Williams TA, Knuiman MW, Finn JC, Ho KM, Dobb GJ, Webb SA,. Effect of an episode of critical illness on subsequent hospitalisation: a linked data study. Anaesthesia 2010; 65: 172-7.
29. Aledort LM,. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
30. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I,. CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS ONE 2011; 6: e18987.